The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Compounds · Semaglutide

About the Semaglutide category

Pinned Wiki Closed
TV
t.vasquezTL4 Moderator29 Mar 2025#1
Community wiki post. Any member at trust level 3 or above can edit this post; every edit is recorded. Last edited by hana.sato on 3 Nov 2025.
  • 3 May 2025 — t.vasquez: Replaced an unsourced figure with the published one and cited it.
  • 28 Apr 2025 — mira.patel: Removed a claim that the cited source did not support.
  • 3 Nov 2025 — hana.sato: Clarified the distinction that was causing repeat questions below.
Editors: t.vasquez, mira.patel, hana.sato
Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

GLP-1 receptor agonist. Dosing, published trial data, tolerability, and formulation questions.

This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a note. If the scope described here has drifted from what actually gets posted, edit it rather than starting a topic about it.

What belongs here

  • Questions specific to semaglutide, with the units and the context stated.
  • Reports and datasets, with the collection method stated.
  • Disagreement about the substance, conducted in public.

What belongs elsewhere

  • Anything urgent belongs in Safety, immediately, and not here.
  • Anything about how this site works belongs in Meta.
  • Requests for a maintained page belong in Wiki requests.

Before posting, it is worth checking the documentation commons and this category's tag pages. A great deal of what gets asked here has a maintained answer with a review date on it, which is more reliable than a two-year-old reply.

59 likes 16mo
JM
j.mwangiTL4 Moderator19 May 2025#2
Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

Moderation notes for this category, so that nothing about how it is run is a surprise.

Topics get moved into and out of here regularly. A move is not a judgement — the category tree is not obvious from outside and putting a question in the wrong place is expected. When I move something I say so in the topic and the action appears in the public log with the guideline cited.

The two guidelines that come up most often in this category are R2, on supplying a source when asked, and R7, on category placement. Neither is used punitively.

16 likes 14mo
RJ
r.jhannsdttirTL3Regular24 Jun 2025#3

As a member rather than staff: the most useful thing I did when I started reading this category was to work through the tag pages rather than the topic list. The topic list shows you what is recent. The tags show you what is settled.

3 likes 13mo
GO
g.oyelaranTL2 Moderator27 Jul 2025#4

Suggestion for the wiki post above: it would be worth linking the two or three most-referenced topics in this category directly, since new members reliably ask for exactly those. Happy to make the edit myself if nobody objects, with a revision note.

0 likes 12mo
MH
ms_hollowayTL4Mass spectrometrist27 Aug 2025 · edited#5
j.mwangi, post #2: Moderation notes for this category, so that nothing about how it is run is a surprise. Topics get moved into and out of here regularly. A move is not a judgement — the category tree is not obvious from outside and putting a question in the wrong place is expected. When I move something I say so in the topic and the action appears in the… Go to post

The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

0 likes in reply to #2 11mo
This topic was closed 90 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

TopicParticipantsRepliesViewsActivity
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since
Posting this under the heading it deserves: Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022)…
HBADNVPNCH+125 132 39k 16mo
Semaglutide versus liraglutide head to head: reading STEP 8 carefully
On the subject in the title: Semaglutide versus liraglutide head to head: reading STEP 8 carefully Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a…
GNKDOJFDS+72 81 1.5k 9mo
Comparing the STEP programme populations: who was actually enrolled
Comparing the STEP programme populations: who was actually enrolled Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med , 2021) with FLOW ( N…
LVBPNN 2 7.5k 2mo
Is there a ceiling dose beyond which semaglutide stops adding benefit?
Is there a ceiling dose beyond which semaglutide stops adding benefit? I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…
NHAVBT 2 14k 2mo
Why semaglutide's albumin binding is the whole reason weekly dosing works
Asking directly, because I could not find a straight answer: Why semaglutide's albumin binding is the whole reason weekly dosing works Session topic: SELECT ( N Engl J Med , 2023). Please read it before…
MMLIYR 2 63k 5mo

Related topics — sharing the tags semaglutide, STEP programme, SELECT trial

TopicParticipantsRepliesViewsActivity
Comparing the STEP programme populations: who was actually enrolled
Comparing the STEP programme populations: who was actually enrolled Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med , 2021) with FLOW ( N…
LVBPNN 2 7.5k 2mo
The arithmetic of an intermediate dose between two label steps
On the subject in the title: The arithmetic of an intermediate dose between two label steps Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am…
MHJHCB 2 136 2mo
The lowest dose that does anything: is that a real question?
Asking directly, because I could not find a straight answer: The lowest dose that does anything: is that a real question? I have read the maintained page on this and I still have a gap, so I am asking rather…
PPDFPGDVS+100 111 9.1k 5mo
Molecular mass of semaglutide and why the figure differs between sources — does this still hold?
Molecular mass of semaglutide and why the figure differs between sources — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 (…
ANHMLSEVT+94 102 14k 19mo
Vagal afferents and the gut-brain pathway — one year on
Vagal afferents and the gut-brain pathway — one year on Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a…
AKTLAW 2 136 11mo